Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Compugen Ltd.
  6. News
  7. Summary
    CGEN   IL0010852080

COMPUGEN LTD.

(CGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Compugen : to Present at the Cantor Global Healthcare Conference

09/14/2021 | 07:12am EST

HOLON, ISRAEL, September 14, 2021 -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that management will present at the Cantor Global Healthcare Conference on Thursday, September 30, 2021 at 1:20 pm ET.

A live webcast of the presentation will be available on the Investor Relations section of Compugen's website at www.cgen.com. A replay will be available following the event.

About Compugen

Compugen is a clinical-stage discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy. Compugen's lead product candidate, COM701, a first-in-class anti-PVRIG antibody, for the treatment of solid tumors, is undergoing Phase 1 studies as a single agent and in dual, and triple combination. COM902, Compugen's second fully owned clinical antibody targeting TIGIT, for the treatment of solid and hematological tumors, is undergoing Phase 1 studies as a single agent and in dual combination. Compugen's therapeutic pipeline also includes early-stage immuno-oncology programs focused largely on myeloid targets. Compugen is headquartered in Israel, with offices in South San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For additional information, please visit Compugen's corporate website at www.cgen.com.

Company contact:

Yvonne Naughton, PhD
Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071

Investor Relations contact:

John Mullaly
LifeSci Advisors, LLC
Email: jmullaly@lifesciadvisors.com
Tel: +1 (617) 429-3548

Disclaimer

Compugen Ltd. published this content on 14 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 September 2021 11:11:00 UTC.


ę Publicnow 2021
All news about COMPUGEN LTD.
11/15Oppenheimer Adjusts Compugen PT to $17 From $19, Maintains Outperform Rating
MT
11/12COMPUGEN : Q3 Earnings Snapshot
AQ
11/12Compugen Narrows Net Loss in Q3, Revenue Gains on Milestone Payment
MT
11/12Press Release dated November 12, 2021 – “Compugen Presents Preliminary Resu..
PU
11/12Compugen Announces Collaboration Expansion with Bristol Myers Squibb alongside $20 Mill..
PU
11/12Compugen Presents Preliminary Results from Phase 1 Dose Escalation Monotherapy Study of..
PR
11/12Compugen Presents Initial Translational Data Supporting the Differentiation of PVRIG Co..
PR
11/12Compugen Presents Preliminary Results from Phase 1/2 Dose Escalation Study of COM701 wi..
PR
11/12Compugen Reports Third Quarter 2021 Results
PR
11/12Compugen Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended Sept..
CI
More news
Analyst Recommendations on COMPUGEN LTD.
More recommendations
Financials (USD)
Sales 2021 7,00 M - -
Net income 2021 -36,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 -10,4x
Yield 2021 -
Capitalization 391 M 391 M -
Capi. / Sales 2021 55,9x
Capi. / Sales 2022 -
Nbr of Employees 68
Free-Float 94,2%
Chart COMPUGEN LTD.
Duration : Period :
Compugen Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends COMPUGEN LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 4,54 $
Average target price 20,57 $
Spread / Average Target 353%
EPS Revisions
Managers and Directors
Anat Cohen-Dayag President, Chief Executive Officer & Director
Ari Krashin Chief Operating & Financial Officer
Paul Jai Sekhri Chairman
Henry Adewoye Chief Medical Officer
Arie Ovadia Director
Sector and Competitors
1st jan.Capi. (M$)
COMPUGEN LTD.-62.51%391
MODERNA, INC.215.53%133 648
LONZA GROUP AG29.85%59 443
IQVIA HOLDINGS INC.46.26%50 064
SEAGEN INC.-3.22%30 994
CELLTRION, INC.-40.39%24 431